KLK3 and prostate cancer: The serum prostate-specific antigen (PSA) test coupled with needle biopsy is the standard clinical practice in prostate cancer diagnosis, but it is limited by the outcomes of excessive negative biopsies, overdiagnosis of clinically insignificant cancers and significant false-negative biopsy rate [1–4].